Altogether, these results suggested that CD8+T cell-targeting fusion protein αPD1-mIL12mut2 had superior antitumor efficacy to the tumor cell-targeting fusion protein αEGFR-IL12mut2, demonstrating that PD-1 targeting is a practical design to maximize the antitumor activity of the IL-12 mutant. The gene discussed is CD8A; the disease is neoplasm.